Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure

Company update AI-generated analysis

🔄 Novo Nordisk rebrands its operational identity as 'Novo' and launches a cultural reset to accelerate execution amid rising competition from Eli Lilly.

💰 The company generated DKK 309.1 billion in sales and DKK 82.3 billion in obesity-care revenue in 2025, maintaining a 59.6% global branded-volume share.

📉 Diabetes market share declined 3.6 percentage points to 30.1%, while the company spent roughly DKK 8 billion on transformation costs in 2025.

⚔️ Rival Eli Lilly is rapidly closing the competitive gap, with Q2 2026 Mounjaro sales jumping 91% to $9.94 billion compared to Novo's lower oral Wegovy performance.

💊 Novo's pipeline includes high-dose Wegovy achieving 20.7% weight loss and recent approval in China for MASH, expanding beyond weight management.

⚠️ Analysts expect a 5%-13% decline in 2026 sales due to pricing pressure, despite the company's strong cash flow and substantial obesity franchise.

📅 CEO Mike Doustdar is seeking to streamline decision-making and accelerate R&D following investor concerns about the pipeline and competitive landscape.

🚀 Novo prepares to unveil new strategic ambitions at its September 21 Capital Markets Day, hoping the reset leads to faster growth before the semaglutide patent cliff.

Bullish Signals
  • Novo Nordisk remains the global obesity-market leader with a substantial 59.6% branded-volume share in 2025, providing a strong foundation for defense against competitors.
  • The company's obesity-care sales rose 31% at constant exchange rates to DKK 82.3 billion in 2025, demonstrating robust growth in its core franchise.
  • Novo's high-dose Wegovy achieved 20.7% weight loss in Phase 3 studies, and the product recently received approval in China for MASH, expanding its therapeutic potential.
  • Wegovy is available in 52 countries by the end of 2025, indicating broad global commercial reach and established distribution networks.
Risk Factors
  • The company's diabetes value-market share fell 3.6 percentage points to 30.1%, signaling a loss of ground in its traditional stronghold.
  • Novo Nordisk spent around DKK 8 billion on transformation costs in 2025, which contributed to a 1% decline in reported operating profit despite sales growth.
  • Oral Wegovy sales of $497 million came in below expectations, highlighting execution challenges in the rapidly evolving oral GLP-1 segment.
  • Analysts project a 5%-13% decline in 2026 sales due to pricing pressure, creating uncertainty around near-term revenue visibility.
  • Rival Eli Lilly is generating faster growth with Q2 2026 Mounjaro sales jumping 91% to $9.94 billion, intensifying competitive pressure on Novo's market share.
Full Analysis
Novo Nordisk A/S (NYSE: NVO) is executing a strategic rebranding initiative, shifting its day-to-day identity to 'Novo' and launching a cultural reset. This move is primarily a response to intensifying competition from Eli Lilly in the obesity-drug market and a perceived loss of momentum, rather than a financial restructuring. The company aims to accelerate decision-making, improve commercial execution, and adopt a more aggressive R&D approach ahead of its September 21 Capital Markets Day. Despite substantial scale with DKK 309.1 billion in 2025 sales and DKK 82.3 billion in obesity-care revenue, Novo faces significant headwinds. Its diabetes market share fell 3.6 percentage points to 30.1%, and it spent approximately DKK 8 billion on transformation costs in 2025. While the company remains the global leader with a 59.6% branded-volume share in obesity, rival Eli Lilly is rapidly narrowing the gap with faster growth in both injectable and oral GLP-1 treatments. The strategic reset carries risks of adding near-term costs without reversing a growth slowdown. Novo's recent oral Wegovy sales missed expectations, and it faces pricing pressure that analysts project could lead to a 5%-13% decline in 2026 sales. While the company possesses a strong foundation with Wegovy available in 52 countries and new approvals for MASH in China, investors are watching closely to see if the cultural shift translates into tangible improvements in pipeline productivity and market share before the upcoming semaglutide patent cliff.